Drug intelligence / Profile preview

cytokine-induced killer cells (The First People's Hospital of Changzhou)

Development stage: Unknown
Lead developer: Changzhou First People's Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Autologous cytokine-induced killer (CIK) cells are an investigational adoptive cellular immunotherapy being developed by The First People's Hospital of Changzhou for the treatment of cholangiocarcinoma. CIK cells are generated by expanding a patient's peripheral blood mononuclear cells ex vivo in the presence of interferon-gamma (IFN-γ), interleukin-2 (IL-2), and anti-CD3 monoclonal antibodies. The resulting cell population is a heterogeneous mix of T lymphocytes, predominantly CD3+CD56+ cells, which possess potent, non-major histocompatibility complex (MHC)-restricted tumoricidal activity. In clinical development, these cells are administered intravenously following radiofrequency ablation (RFA) to target residual tumor cells and prevent recurrence in patients with unresectable cholangiocarcinoma.

Other names: CIK cellsautologous cytokine-induced killer cellscytokine-induced killer cells

Targets

ICAM1 (Intercellular Adhesion Molecule 1)MICB (Major histocompatibility complex class i-related protein B)

Beyond the preview

Go deeper on cytokine-induced killer cells (The First People's Hospital of Changzhou).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cytokine-induced killer cells (The First People's Hospital of Changzhou).

Explore the full profile